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Abstract
Background: There is little information on nasopharyngeal (NP) flora or bacteremia in HIV-
infected children. Our aim was to describe the organisms and antimicrobial resistance patterns in
children enrolled in a prospective study comparing daily and three times weekly trimethoprim-
sulfamethoxazole (TMP-SMX) and isoniazid (INH) or placebo prophylaxis.
Methods: NP swabs were taken at baseline from HIV-infected children enrolled in the study.
Standard microbiological techniques were used. Children were grouped according to previous or
current exposure to TMP-SMX and whether enrolled to the study during a period of
hospitalization. Blood culture results were also recorded within 12 months of baseline.
Results: Two hundred and three children, median age 1.8 (Interquartile [IQ]: 0.7–4) years had NP
swabs submitted for culture. One hundred and eighty-four (90.7%) had either stage B or C HIV
disease. One hundred and forty-one (69.8%) were receiving TMP-SMX and 19 (9.4%) were on
antiretroviral therapy. The majority, 168 (82%) had a history of hospitalization and 91 (44.8%) were
enrolled during a period of hospitalization. Thirty-two subjects (16.2%) died within 12 months of
study entry.
One hundred and eighty-one potential pathogens were found in 167 children. The most commonly
isolated organisms were Streptococcus pneumoniae (48: 22.2%), Gram-negative respiratory
organisms (Haemophilus influenzae and Moraxella catarrhalis) (47: 21.8%), Staphylococcus aureus (44:
20.4%), Enterobacteriaceae 32 (14.8%) and Pseudomonas 5 (2.3%).
Resistance to TMP-SMX occurred in > 80% of pathogens except for M. catarrhalis (2: 18.2% of
tested organisms). TMP-SMX resistance tended to be higher in those receiving it at baseline (p =
0.065). Carriage of Methicillin resistant S. aureus (MRSA) was significantly associated with being on
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TMP-SMX at baseline (p = 0.002). Minimal inhibitory concentrations (MIC) to penicillin were
determined for 18 S. pneumoniae isolates: 7 (38.9%) were fully sensitive (MIC ≤ 0.06 µg/ml), 9 (50%)
had intermediate resistance (MIC 0.12 – 1 µg/ml) and 2 (11.1%) had high level resistance (MIC ≥2
µg/ml). Fifty percent of Enterobacteriaceae produced extended spectrum beta-lactamases (ESBL)
(resistant to third generation cephalosporins) and 56% were resistant to gentamicin. Seventy-seven
percent of S. aureus were MRSA. Carriage of resistant organisms was not associated with
hospitalization.
On multivariate logistic regression, risk factors for colonization with Enterobacteriaceae were age
≤ one year (Odds ratio 4.4; 95% Confidence Interval 1.9–10.9; p = 0.0008) and CDC stage C
disease (Odds ratio 3.6; 95% Confidence Interval 1.5–8.6; p = 0.005)
Nineteen (9.4%) subjects had 23 episodes of bacteremia. Enterobacteriaceae were most commonly
isolated (13 of 25 isolates), of which 6 (46%) produced ESBL and were resistant to gentamicin.
Conclusion: HIV-infected children are colonized with potential pathogens, most of which are
resistant to commonly used antibiotics. TMP-SMX resistance is extremely common. Antibiotic
resistance is widespread in colonizing organisms and those causing invasive disease. Antibiotic
recommendations should take cognizance of resistance patterns. Antibiotics appropriate for ESBL-
producing Enterobacteriaceae and MRSA should be used for severely ill HIV-infected children in
our region. Further study of antibiotic resistance patterns in HIV-infected children from other areas
is needed.
Background
There are few data on nasopharyngeal (NP) flora from
HIV-infected children. Most studies have focused on spe-
cific organisms such as Streptococcus pneumoniae, Staphylo-
coccus aureus and Haemophilus influenzae, with provision of
limited antibiotic resistance data, mainly to penicillin [1-
5]. Although antibiotic resistance has been documented
in some of these studies, there is need for more informa-
tion. Thus far, there are no studies documenting the pres-
ence of other potential pathogens.
Colonization of the NP by potential respiratory patho-
gens S. pneumoniae, H. influenzae, S. aureus and Moraxella
catarrhalis  is established early in childhood. Factors
involving colonization and elimination are not well
understood but probably involve adhesive and immuno-
logic factors [6]. NP colonization with Enterobacteriaceae
occurs in malnourished children and also those from
impoverished environments [7,8]. That NP colonization
precedes invasive disease has been well established in the
rat model [9], meningococcal meningitis [10] and for S.
pneumoniae in children [11,2]. Pharyngeal colonization by
Salmonella species in resource-poor settings has also been
linked to invasive disease [12].
There are few data in HIV-infected children on organisms
causing bacteremia. Madhi et al documented an increased
risk of MRSA and trimethoprim-sulfamethoxazole (TMP-
SMX) resistance in HIV-infected compared to uninfected
infants with bacteremic community-acquired pneumonia
in 2000 [13].
TMP-SMX prophylaxis, given to all HIV-exposed and
infected children from 6 weeks of age to prevent Pneumo-
cystis jirovecii pneumonia (PCP) has been associated with
NP carriage of multiresistant S. pneumoniae [14] and
increased colonization with S. aureus [15]. Moreover, its
use for intercurrent infections such as otitis media, is
linked to increased resistance [16].
The aim of this study was to describe the baseline bacterial
flora and antimicrobial resistance patterns of potentially
pathogenic bacteria in HIV-infected children enrolled in a
prospective study investigating the long-term effects of
TMP-SMX and INH prophylaxis [17]. Secondary aims
were to examine the effects of prior TMP-SMX on NP
organisms and TMP-SMX resistance and to explore rela-
tionships between colonizing flora, nutritional status,
age, extent of HIV disease, and hospitalization status.
Lastly, blood culture isolates, which represent the most
extreme form of invasive disease, were reviewed.
Methods
Study population
The study population comprised HIV-infected children
aged 8 weeks or older, attending either Red Cross (RCCH)
or Tygerberg Children's Hospitals (TCH) in Cape Town
and recruited for a study of daily versus thrice weekly
TMP-SMX given with Isoniazid (INH) or placebo [17].
The study commenced in December 2002. Due to
resource constraints, no HIV-uninfected infants were
recruited as controls. The Ethics Committees of Cape
Town and Stellenbosch Universities approved the study.BMC Infectious Diseases 2008, 8:40 http://www.biomedcentral.com/1471-2334/8/40
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Written, informed consent was obtained from a parent or
legal guardians prior to enrolment.
At enrolment, note was taken of previous and current hos-
pitalization, concomitant medication, including TMP-
SMX and antiretroviral therapy. According to baseline
TMP-SMX prophylaxis status, subjects were grouped as
follows: 1) no prophylaxis, 2) currently receiving TMP-
SMX 3) TMP-SMX not currently used but given in the past.
Race was not documented in subjects. All came from
socio-economically deprived settings and attended public
healthcare facilities. The median household income was
$126 per month, with on average 5 persons per house-
hold, translating into $0.84/person/day and below the
monthly minimum subsistence of $133 defined by the
South African Government. Nearly half (44%) of children
lived in informal settlements [18].
Subjects were classified for severity of HIV disease and
CD4 cell depletion according to the Centres for Disease
Control and Prevention (CDC) classification system. [19]
Weight for age Z-score was calculated using Epi-Info 2004,
CDC, Atlanta, GA. Mortality data for the first 52 weeks on
the study was extracted from the trial database. Blood cul-
ture data were obtained from the National Health Labora-
tory databases at the two hospitals from a week prior until
52 weeks post enrolment.
Laboratory methods
NP swabs, (urethral/ENT straight wire swabs transported
in Amies charcoal media (Medical wire & equipment,
Wiltshire, U.K) were collected at baseline according to a
prescribed protocol. A single microbiologist processed all
specimens. Swabs were inoculated on appropriate media
to isolate staphylococci, streptococci (including S. pneu-
moniae), H. influenzae, M. catarrhalis and other Gram-neg-
ative organisms. After incubation, organisms were
identified according to routine laboratory procedures.
Susceptibility testing (Kirby-Bauer disc diffusion) was per-
formed on all isolates and interpreted according to Clini-
cal Laboratory Standards Institute (CLSI) [20]. For M.
catarrhalis, β-lactamase production was determined using
a nitrocephin method (Oxoid, Hampshire, England). The
prescribed quality control strains of the American Type
Culture Collection (ATCC) were used to verify all suscep-
tibility tests. Extended spectrum beta-lactamase (ESBL)
production was detected using the double disc diffusion
test, by placing a disc with amoxicillin/clavulanate adja-
cent to discs with cefotaxime and ceftazidime (1 disc with
each), and looking for synergy between the clavulanic
acid and the cephalosporin [21]. MRSA was detected
using oxacillin discs on salt agar [22].
Isolates of S. pneumoniae, H. influenzae and M. catarrhalis
were stored at -70°C in a glycerol nutrient broth enriched
with 5% horse blood. Broth dilution MIC's were per-
formed in batches according to CLSI methodology. A sin-
gle microbiologist (JS) processed all NP swabs.
M. catarrhalis and H. influenzae were categorized as Gram-
negative respiratory organisms and all Enterobacteriaceae
were grouped together. Subjects with no growth, contam-
inated cultures, coagulase negative staphylococci or only
commensals were also combined into a single group.
Statistics
Descriptive statistics used to summarize ordinal and con-
tinuous variables were the median and interquartile range
(IQR). The chi-square and Fisher's exact tests were used
for analysis of categorical data and the Kruskal-Wallis test
was used for non-parametric one-way analysis of variance.
A multiple logistic regression model was used to deter-
mine risk factors for colonization by predominant organ-
isms. Odds ratios and 95% confidence intervals were
reported. The model included all factors from bivariate
analyses evaluated a significance level of 0.1. Analyses
with performed using JMP 5.1 (SAS, Cary, CA, USA).
Results
NP cultures were submitted for 203 children. Baseline
demographics are shown in Table 1. Median age was 1.8
(IQ 0.7 – 4 years. The majority (89.7%) of children had
moderate or severe HIV disease and 78% had CD4 cell
depletion. The median weight for age-Z score (WAZ) was
-1.6. Almost 70% were receiving TMP-SMX at baseline.
The majority of subjects had been hospitalized previously,
with only 38 subjects (18.7%) never having been hospi-
talized. Almost half (44.8%) were recruited during a
period of hospitalization. Nineteen (9.4%) children were
on antiretroviral therapy (ART). Thirty-five children
(17.2%) died within 12 months of enrolment.
Infants without prior TMP-SMX were significantly
younger than those on TMP-SMX at baseline (1.3 [IQ:
0.2–2.1] versus1.9 [IQ: 0.4–4.4] years) or than those pre-
viously on TMP-SMX (3.2 [IQ: 1.8–6.3 years) (p =
0.0008). NP organisms and TMP-SMX status are shown in
Table 2. One hundred and eighty-one potential pathogens
were isolated from 167 subjects. Five had two organisms
within a group, such as H. influenzae and M. catarrhalis or
different species of Gram-negative Enterobacteriaceae.
The most common organisms were S. pneumoniae (48:
22%), Gram-negative respiratory organisms (H. influenzae
and M. catarrhalis) (47: 21.7%), S. aureus (44: 20.4%),
and Enterobacteriaceae (32: 14.1%). There were no signif-
icant differences in organisms isolated by TMP-SMX sta-
tus, except for P. aeruginosa and Acinetobacter which were
more common in subjects not on TMP-SMX at baseline (p
= 0.01 and 0.048, respectively).BMC Infectious Diseases 2008, 8:40 http://www.biomedcentral.com/1471-2334/8/40
Page 4 of 10
(page number not for citation purposes)
Risk factors for colonization by predominant organisms
are shown in Table 3. For Enterobacteriaceae, age below a
year (OR 4.4 [1.9–10.9]) and CDC Stage C disease (OR
3.6 [1.5–8.6]) were significant factors on multivariate
analysis. For S. aureus, having moderate or severe CD4
depletion was associated with colonization (OR 3.4 (1.3–
11.8]). There was a trend towards decreased carriage of
gram-negative respiratory organisms in subjects on TMP-
SMX at baseline (OR 0.3 [0.09–0.9] p = 0.057) and also
with a relative lack of CD4 depletion (CDC Immunologi-
cal Class 2 or 3: OR 0.3 [0.1–0.9] p = 0.005). No risk fac-
tors were identified for S. pneumoniae carriage.
Antibiotic resistance patterns are shown in table 4. One
hundred and forty-two (88%) of 160 isolates tested, were
resistant to TMP-SMX. A high percentage of organisms
were resistant to first line antibiotics used for severe com-
munity acquired infections. Seventy-seven percent of S.
aureus were MRSA and 81% were resistant to gentamicin.
For S. pneumoniae, 20 of 48 (42.7%) were resistant to pen-
icillin by oxacillin screening and one (2.1%) was resistant
to cefotaxime. MIC's for penicillin were determined for 18
isolates, of which 7 (38.9%) were fully sensitive (MIC ≤
0.06 µg/ml), 9 (50%) had intermediate resistance (MIC
0.12 – 1 µg/ml) and 2 (11.1%) had high level resistance
(MIC ≥2 µg/ml). Sixteen of 32 (50%) Enterobacteriaceae
produced extended-spectrum beta-lactamase (ESBL), thus
resistant to third generation cephalosporins. Eighteen
(56%) were resistant to gentamicin and 5 (15.6%) to ami-
kacin.
Table 1: Baseline demographic data in HIV-infected children with NP specimens
Patients N = 203
Female 96 (47.3%)
Median age (IQ range) 1.8 (0.7 – 4) years
CDC Clinical Class
N 2 (0.9%)
A 17 (8.4%)
B 138 (68%)
C 46 (22.7%)
CDC Immunological
1 44 (22%)
2 85 (42.5%)
3 71 (35.5%)
CD4 percentage 19 (14 – 26)
Hospitalization
None in past 52 (25.6%)
1 54 (26.6%)
2 53 (26.11%)
3 28 (13.79%)
4 11 (5.42%)
5 5 (2.46%)
Recruited to study during or immediately after current hospitalization 91 (44.8%)
No hospitalization 38 (18.7%)
TMP-SMX status
No previous experience 47 (23.3%)
On drug at baseline 141 (69.8)
History of exposure 15 (7.4%)
Median weight for age Z-score (IQ range) -1.6 (-3 – -0.4)
Antiretroviral therapy at baseline 19 (9.4%)
Time on therapy 0.5 (0.2 – 1.1) years
Died within 12 months of enrolment 35 (17.2%)BMC Infectious Diseases 2008, 8:40 http://www.biomedcentral.com/1471-2334/8/40
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The influence of baseline status of TMP-SMX on resistance
is shown in Table 5. Baseline levels of resistance to TMP-
SMX were high, regardless of status but there was a trend
for higher resistance to TMP-SMX in subjects receiving it at
baseline (p = 0.065). MRSA was significantly associated
with baseline TMP-SMX (87% of subjects; p = 0.002) even
though baseline resistance in those never having received
TMP-SMX was also high (70%).
In subjects without a history of previous or current hospi-
talization, antibiotic resistance in the most common
organisms isolated was not reduced. Unexpectedly, for S.
pneumoniae, TMP-SMX resistance was significantly more
common in subjects without a history of hospitalization.
(Table 6)
Bacteremias are shown in Table 7. Nineteen subjects
(9.4%) had 23 episodes of bacteremia. Four had two epi-
sodes and three had two pathogens from a single blood
culture. The bacteremias occurred a median of 30.3 (IQ:
4.6 – 36.6) weeks post enrolment. Only one subject had
bacteremia prior to enrolment (3 days). Enterobacteriacae
were the most commonly isolated group. More than 50%
produced ESBL and were also resistant to gentamicin,
showing a similar profile to NP isolates. Reduced suscep-
tibility to penicillin occurred in 3 of 4 S. pneumoniae iso-
lates.
Three of four subjects with the same organism isolated
from nasopharynx and blood had identical resistance pat-
terns. One had ESBL-producing and gentamicin-resistant
K. pneumoniae. Another had Enterobacter, sensitive to 3rd
generation cephalosporins and gentamicin and a third
had S. pneumoniae with intermediate resistance to penicil-
lin. The fourth subject had MRSA in the nasopharynx but
no sensitivity information for the blood culture isolate.
Table 2: Pathogenic NP organisms and TMP-SMX status at baseline
Total Not on TMP-SMX at 
baseline
On TMP-SMX at baseline Previously received TMP-
SMX
†Pathogenic organisms
S. pneumoniae 48 (26.5%) 9 (5%) 36 (19.9%) 3 (1.7%)
§Gram negative respiratory 
organism (M. catarrhalis, H. 
influenzae)
48 (26.5%) 7 (3.2%) 35 (19.3%) 6 (3.3)
S. aureus 44 (24.3%) 10 (5.5%) 31 (17.1%) 3 (1.7%)
Enterobacteriacae 32 (17.7%) 13 (9.9%) 18 (9.9%) 1 (0.5%)
Non-fermenters including 
Pseudomonas aeruginosa #
5 (2.8%) 4 (2.2%) 1 (0.5%) 0
Acinetobacter species ¶ 4 (2.2%) 3 (1.7%) 1 (0.5%) 0
† 10 subjects had 2 organisms and 2 had 3 organisms isolated from a NP swab.
§M. catarrhalis n – 22; H. influenzae – n – 26
TMP-SMX exposure: More than 1 organism per subject
Organisms not included – Coagulase negative staphylococcus – 10; Streptococcus viridans – 2; other commensals – 11; no growth – 10; 
contaminants – 3
# p = 0.0104 (Fisher's Exact 2-tail test)
¶p = 0.048 (Fisher's Exact 2-tail test)
Table 4: NP isolates and resistance to TMP-SMX and other selected antimicrobials
Organisms isolated Resistant to TMP-SMX Resistance to selected antibiotics
S. pneumoniae 43 (89.6%) Pen 20 (41.7%)# CTX 1 (2.1%)
Gram negative respiratory
H. influenzae 20 (80%) Amp 3 (12%); Amox/clav 1 (4%)
M. catarrhalis 2 (18.2%) ∆ † Beta-lactamase +ve 12 (85.7%)
S. aureus 40 (91%) Clox – 34 (77.3%) Gent 36 (81.8%), Amik – 0
Enterobacteriaceae 29 (90.6%) CTX 16 (50%); Gent 18 (56%); Amik 5 (15.6%); PTZ 10 – 31.3%) Mero – 0
Pseudomonas 0 Gent – 1 (20%); Amik – 0
Clox – cloxacillin, Gent – gentamicin, Amik – amikacin, Pen – penicillin; CTX – cefotaxime; Amp – ampicillin, Amox/clav – amoxicillin-clavulanate
# S. pneumoniae – MIC performed in 18 isolates: 7 (38.9%) fully sensitive (MIC ≤ 0.06 µg/ml) 9 (50%) with intermediate resistance (MIC 0.12 – 1 µg/
ml) and 2 (11.1%) with high level resistance (MIC ≥2 mg/ml) to penicillin
M. catarrhalis: ∆ 11 isolates tested for MIC; † 14 of 17 isolates tested for beta-lactamase production. No significant differences for resistance to 
penicillin, cloxacillin, cefotaxime, gentamicin, amikacin and TMP-SMX by present or previous exposure to TMP-SMXBMC Infectious Diseases 2008, 8:40 http://www.biomedcentral.com/1471-2334/8/40
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Discussion
Our study confirms a high carriage of potential patho-
gens, many of which are antibiotic resistant, from NP and
blood culture isolates in HIV-infected children. The
majority of organisms from both NP and blood were
resistant to TMP-SMX and other antibiotics commonly
used for community-acquired infection. A disturbing
finding was the high prevalence of MRSA and ESBL-pro-
ducing Enterobacteriaceae from both sites.
The demographic features of HIV-infected children are
similar to those described previously at the Tygerberg
Family clinic where the majority were under two years of
age, had moderate or severe immunosuppression and
symptomatic HIV disease [23]. Mortality has been
described elsewhere and was not analyzed further as it
may have been affected by multiple factors beyond the
scope of this report [17]. The significant difference in age
of subjects stratified by TMP-SMX exposure probably
reflects utilization of the public health service. Subjects
entered the study from January 2003, as the Vertical Trans-
Table 3: Risk factors for colonization by selected bacteria.
Organism Odds ratio (95% CI) Bivariate p-value Multivariate logistic regression Wald p-values
Enterobacteriaceae
Age < 1 year 4.6 (2–11.1) 0.0004 4.4 (1.9–10.9) 0.0008
Stage C disease 3.7 (1.6–8.6) 0.002 3.6 (1.5–8.6) 0.005
Female 0.5 (0.23–1.19) 0.13
CDC Immunological Class 2 or 3 2 (0.7–6.9) 0.23
Weight for age-Z-score <-2 1.6 (0.7–3.5) 0.27
No prior TMP-SMX at baseline 0.3 (0.03–1.3) 0.22
Present and/or previous hospitalization 1.1 (0.4–3.7) 0.9
S. aureus 1 (0.3–3.8) 1
Age < 1 year 1.2(0.6–2.4) 0.6
Stage C 0.1 (0.6–2.9) 0.4
Weight for age-Z-score <-2 2 (1–3.9) 0.051 1.7 (0.8–3.5) 0.11
CDC Immunological Class 2 or 3 3.7 (1.4–12.9) 0.007 3.4 (1.3–11.8) 0.029
Female 1.2 (0.63–2.4) 0.54
No prior TMP-SMX at baseline 0.97 (0.42–2.1) 0.94
Present and/or previous hospitalization 2.04 (0.8–6.3) 0.14
S. pneumoniae
Age < 1 year 0.53 (0.2–1.1) 0.09
Stage C 0.51 (0.2–1.6) 0.13
Weight for age-Z-score <-2 0.71 (0.4–1.4) 0.31
CDC Immunological Class 2 or 3 0.8 (0.4–1.6) 0.5
Female 0.97 (0.5–1.9) 0.92
No prior TMP-SMX at baseline 1.4 (0.4–5.3) 0.67
Present and/or previous hospitalization 0.64 (0.29–1.46) 0.28
Gram-negative respiratory organisms
Age < 1 year 0.53 (0.2–0.98) 0.055 0.59 (0.24–1.33) 0.22
Stage C 0.8 (0.3–1.7) 0.51
Weight for age-Z-score <-2 0.46 (0–0.9) 0.029 0.55 (0.25–1.2) 0.14
CDC Immunological Class 2 or 3 0.32 (0.16–0.66) 0.002 0.33 (0.15–0.71) 0.005
Female 1.4 (0.75–2.8) 0.28
No prior TMP-SMX at baseline 5.1 (1.4–22.1) 0.058 0.33 (0.09–0.94) 0.057
Present and/or previous hospitalization 0.5 (0.23–1.12) 0.094 0.63 (0.27–1.54) 0.3
Multivariate logistic regression only where p ≤ 0.1 on univariate analyses
N = 203
Table 5: Relationship between TMP-SMX status at baseline and antibiotic resistance in NP isolates
Antibiotic Total isolates tested Not on TMP-SMX at 
baseline Resistance (%)
On TMP-SMX at baseline 
Resistance (%)
Previously received TMP-
SMX Resistance (%)
P-value
TMP-SMX 151 31 (86.1%) 93 (91.2%) 9 (69.2%) 0.065
Cloxacillin 44 7 (70%) 27 (87.1) 0 0.002
Cefotaxime 32 7 (53.9%) 9 (50%) 0 0.58BMC Infectious Diseases 2008, 8:40 http://www.biomedcentral.com/1471-2334/8/40
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mission Prevention program was gradually being intro-
duced in the Western Cape. Consequently, many of the
older infants and children were only identified through
knowledge of their parents' HIV status, or when present-
ing with clinical disease suggestive of HIV. Those never
exposed to TMP-SMX were significantly younger than
those already on TMP-SMX. Those previously on the drug
but not receiving it at baseline were older, possibly reflect-
ing poor retention in the public health system.
Colonization by S. pneumoniae,  H. influenzae and  M.
catarrhalis  is well documented in early childhood [6].
Approximately 50% of children carry S. pneumoniae at two
years of age, declining to 20% by 7 years. Below 7 years of
age 40% of immunocompetent children in developed
countries carry M. catarrhalis and 30% H. influenzae [24].
Socioeconomic factors such as housing, overcrowding,
poor hygiene, access to health care and daycare are major
determinants of colonization. For example, in Australia,
Aboriginal children are colonized with M. catarrhalis, H.
influenzae and S. pneumoniae by 20 days of age, whereas
non-Aboriginal children acquire these organisms after
200 days of age [25]. Increased numbers of colonizing fae-
cal organisms such as Enterobacteriaceae and Pseu-
domonas have been found in malnourished infants and
children from resource-poor settings in the pre-HIV era
[7,8]. A recent comparative community-based study of
children aged between 4 months and 5 years, showed
more frequent carriage of Gram-negative enteric patho-
gens in Brazilian (50%) and Angolan (57%) than Dutch
children (4%) [26].
Studies on NP S. pneumoniae in HIV-infected adults and
children from developed countries showed similar car-
riage rates to uninfected subjects [27,3,28]. In Kenya,
Rusen et al found no increased NP S. pneumoniae coloni-
zation in asymptomatic HIV-infected infants (20%) com-
pared to seronegative controls (22%) [5].
In our study, colonization by Enterobacteriaceae was asso-
ciated with age below a year and advanced HIV disease. S.
aureus was linked to CD4 depletion and Gram-negative
respiratory organisms to absence of CD4 depletion. High
carriage rates of S. aureus and possible relationship with
invasive disease, has been noted in HIV-infected adults
[29,30]. In a study from the Western Cape, comparing
community acquired pneumonia in HIV-infected and
uninfected infants, Zar et al found a higher rate of S. aureus
in nasopharyngeal aspirates and invasive disease, linking
this finding to TMP-SMX prophylaxis in HIV-positive chil-
dren [15]. Similarly, in a recent survey of children hospi-
talized with severe pneumonia in Kwazulu-Natal, South
Africa, HIV-infected children were significantly more
Table 6: Current or previous hospitalization: relationship to selected NP organisms and antibiotic resistance
Organism No current or previous hospitalization (% organisms) Antibiotic resistance (% tested for selected antibiotic) P-value
S. aureus 5 (11.4%) Cloxacillin – 4 (80%) 1
TMP-SMX – 5 (100%) 1
S. pneumoniae 12 (25%) Penicillin – 7 (58.3%) 0.2
TMP-SMX – 8 (66.7%) 0.011
Enterobacteriaceae 6 (18.8%) Cefotaxime 3 (50%) 1
Gentamicin 6 (50%) 0.5
TMP-SMX 6 (83.3%) 0.48
Fisher's Exact 2-tail test
Table 7: Blood culture isolates and antibiotic resistance patterns
Organisms isolated Number Resistant to TMP-SMX Resistance to selected antibiotics
S. pneumoniae 4 1 (only 1 tested) Pen sensitive 1; intermediate resistance 2; resistant 1
Gram negative respiratory H. influenzae 2 2 (100%) Amp 0 (0%)
S. aureus* 3 2 (66.6%) Clox – 2 (77.3%) Gent 2 (81.8%), Amik – 0
Enterobacteriacae† 13 8 (72.3%) CTX – 6 (54.5%); Gent – 6 (54.5%); Amik – 1 (10%); PTZ -10 
(31.3%) Mero – 0
Acinetobacter 1 0 CTX – 0; gent – 0
Pseudomonas 1 1 PTZ -1; Gent – 1; Amik – 1
Shigella flexneri 1 1 Amp – 0; gent -1
*No data for one isolate
† Two isolates had no data for for cefotaxime, gentamicin and TMP-SMX; Three had no data for amikacin
Clox – cloxacillin; Gent – gentamicin; Amik – amikacin; Pen – penicillin; Amp – ampicillin; CTX – cefotaxime; PTZ – piperacillin/tazobactam; Mero – 
meropenemBMC Infectious Diseases 2008, 8:40 http://www.biomedcentral.com/1471-2334/8/40
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likely to be colonized with S. aureus (31%) than HIV-
uninfected children (13.8%) [2].
TMP-SMX resistance occurs commonly in children. For
example in a recent survey of H. influenzae colonization in
daycare attendees in Brazil, 46% were resistant to TMP-
SMX and 10% had multidrug resistance [31]. Although
not reported, HIV prevalence was likely to be extremely
low. Abdel-Haq showed that both young age and TMP-
SMX prophylaxis were risk factors for NP colonization
with multiply resistant S. pneumoniae in immunocompro-
mised and immunocompetent children from Detroit,
USA [14].
Antibiotic resistance was extremely common in our study.
Between 80 – 90% of most pathogens (except for M
catarrhalis) were resistant to TMP-SMX. Almost 80% of S.
aureus were methicillin-resistant and 50% of Enterobacte-
riaceae had ESBL production. The majority of children
had advanced disease and frequent contact with both in-
and outpatient hospital facilities. High prevalence of anti-
biotic resistance has already been described in malnour-
ished children with pneumonia and also in children with
hospital-associated bacterial infection [32,33]. We did not
record TMP-SMX usage or frequency of healthcare utiliza-
tion in other family members, but speculate that both
were likely to be high, as other family members are also
likely to be HIV-infected. The children enrolled in the
study come from poor socio-economic conditions where
overcrowding and spread of antibiotic resistant pathogens
in homes are likely. As we did not link previous hospital-
ization with antibiotic resistance in NP organisms, we
speculate that antibiotic resistance is well established in
homes of study subjects and possibly in the communities,
as well. As evidence of this, TMP-SMX resistance was sig-
nificantly higher in S. pneumoniae in subjects without a
history of hospitalization. Also, even though we found
significantly more MRSA in children on TMP-SMX at base-
line, 70% of those not on TMP-SMX also had MRSA, sup-
porting the contention that the organism is well
established in the homes of the infants. A major limita-
tion of our study is that we did not document NP coloni-
zation in HIV-uninfected children from the same
communities or within the household of our subjects. We
plan to address these issues.
Colonization with antibiotic resistant organisms has been
noted in surveys of African children and adults. In 1997,
Woolfson described S. pneumoniae in 72% of 260 Zam-
bian school children < 6 years of age. Antibacterial resist-
ance occurred in 34.1% of isolates; intermediate
resistance to penicillin occurred in 14.3% and to TMP-
SMX in 12.7% [34]. In the Kenyan study from 1997,
Rusen et al documented that 60% of S. pneumoniae iso-
lates had intermediate resistance to penicillin [5]. Both
studies preceded the widespread use of TMP-SMX for che-
moprophylaxis in HIV-infected infants [35]. MRSA has
been found more commonly in HIV-infected than unin-
fected children in Kwazulu-Natal, South Africa [2].
The incidence of bacteremia (9.4%) is higher that from a
survey in the pre-HIV era. In a study of hospitalized chil-
dren at Tygerberg Hospital in 1989, 2% had bacteremia,
the most frequent isolates being S. pneumoniae and  S.
aureus. In community-acquired infections, pathogens
were also sensitive to first line antibiotics [36]. In a study
of infants with severe lower respiratory tract infection in
Soweto,  S. pneumoniae and  S. aureus from bacteremic
infants showed significantly higher levels of penicillin (54
versus 23%) and methicillin resistance (60% versus 0%)
respectively in HIV-infected than uninfected infants [13].
Community-associated infection due to MRSA is an
emerging problem in children from developed countries
[37,38]. In contrast, community-associated infection due
to ESBL-producing organisms is well documented in
adults, but not yet in children [39].
The colonizing NP flora and high level of antibiotic resist-
ance for Enterobacteriaceae and S. aureus suggest that
empiric antibiotic treatment should be adapted to cover
MRSA and ESBL-producing Enterobacteriaceae. Also, ami-
kacin is a more appropriate aminoglycoside than gen-
tamicin for severely ill HIV-infected children in our
region. A limitation of our study, however, is that we did
not distinguish between community and hospital
acquired bacteremia or nasopharyngeal colonization. To
our knowledge, this is the first documentation of ESBL-
producing Enterobacteriaceae causing bacteremia or colo-
nizing the nasopharynx in HIV-infected children.
Conclusion
The majority of HIV-infected children were colonized
with pathogenic organisms, with high levels of antibiotic
resistance. These included respiratory isolates such as S.
pneumoniae, H. influenzae and M. catarrhalis, and gram-
negative organisms such as Enterobacteriaceae and Pseu-
domonas. The spectrum of antibiotic resistance in blood
culture isolates is similar to that found in the nasophar-
ynx. These findings have implications for empiric antibi-
otic therapy in sick HIV-infected children. We recommend
antibiotics appropriate for ESBL-producing Enterobacte-
riaceae and MRSA in severely ill HIV-infected children in
our setting. However, there is also concern that wide-
spread use of broader spectrum agents may lead to resist-
ance to these agents as well. There is an urgent need to
further document the spectrum and antibiotic resistance
profiles of HIV-infected children in under-resourced com-
munities.BMC Infectious Diseases 2008, 8:40 http://www.biomedcentral.com/1471-2334/8/40
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